Skip to Content

Generic Aklief Availability

Last updated on July 7, 2021.

Aklief is a brand name of trifarotene topical, approved by the FDA in the following formulation(s):

AKLIEF (trifarotene - cream;topical)

Has a generic version of Aklief been approved?

No. There is currently no therapeutically equivalent version of Aklief available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Aklief. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof
    Patent 7,807,708
    Issued: October 5, 2010
    Inventor(s): Biadatti; Thibaud & Dumais; Laurence & Soulet; Catherine & Talano; Sandrine & Daver; Sebastien
    Assignee(s): Galderma Research & Development

    Novel ligand compounds having the general formula (I): and pharmaceutical/cosmetic compositions comprised thereof are useful in human and veterinary medicine or, alternatively, in cosmetics.

    Patent expiration dates:

    • October 1, 2026
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Ligands that modulate RAR receptors
    Patent 8,227,507
    Issued: July 24, 2012
    Inventor(s): Biadatti; Thibaud & Dumais; Laurence & Soulet; Catherine & Talano; Sandrine & Daver; Sebastien
    Assignee(s): Galderma Research & Development

    Novel ligand compounds having the general formula (I): and pharmaceutical/cosmetic compositions comprised thereof are useful in human and veterinary medicine or, alternatively, in cosmetics.

    Patent expiration dates:

    • December 21, 2025
      ✓ 
      Patent use: TOPICAL TREATMENT OF ACNE VULGARIS
  • Ligands that modulate RAR receptors
    Patent 8,470,871
    Issued: June 25, 2013
    Assignee(s): Galderma Research & Development

    Novel ligand compounds having the general formula (I): and pharmaceutical/cosmetic compositions comprised thereof are useful in human and veterinary medicine or, alternatively, in cosmetics.

    Patent expiration dates:

    • December 21, 2025
      ✓ 
      Patent use: METHOD OF ACTIVATING RARGAMMA RECEPTOR
  • Topical compositions containing a retinoid of the oil-in-water emulsion type
    Patent 9,084,778
    Issued: July 21, 2015
    Assignee(s): GALDERMA RESEARCH & DEVELOPMENT

    A composition in the form of an oil in water emulsion, preferably without emulsifier, is described. The composition can include, in a physiologically acceptable environment, at least one new retinoid. Also described, is the method of preparing the composition and its use in cosmetics and dermatology.

    Patent expiration dates:

    • May 30, 2033
      ✓ 
      Patent use: TREATMENT OF ACNE VULGARIS
      ✓ 
      Drug product
  • Topical compositions in the form of a gel containing a particular solubilized retinoid
    Patent 9,498,465
    Issued: November 22, 2016
    Assignee(s): GALDERMA RESEARCH & DEVELOPMENT

    A composition in the form of a gel, preferably hydroglycolic, is described. The composition can include in a physiologically acceptable medium, at least one particular retinoid. Also described, is a method for the preparation thereof and the cosmetic and dermatological use of the same.

    Patent expiration dates:

    • May 30, 2033
      ✓ 
      Patent use: TOPICAL TREATMENT OF ACNE VULGARIS
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • October 4, 2024 - NEW CHEMICAL ENTITY

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.